Urovant Sciences Shares Double on Sumitovant Biopharma Buyout Offer

November 16, 2020

Source: Streetwise Reports   11/13/2020

Shares of Urovant Sciences traded 93% higher to a new 52-week high after the company reported that it entered into a definitive agreement to be acquired by Sumitovant Biopharma for $16.25 per share in cash.

After U.S. markets closed for trading yesterday afternoon, clinical-stage biopharmaceutical company Urovant Sciences Ltd. (UROV:NASDAQ), which is engaged in the development and commercialization of therapies for urologic conditions, announced that it entered into a definitive agreement to be acquired by Sumitovant Biopharma in a transaction valued at approximately $584 million based up an offer price of $16.25 per share in cash.

The firm noted that Sumitovant is currently its largest shareholder with approximately 72% equity ownership of the company. The company stated that the $16.25 per share offer price equates to a 92% premium over the 30-day volume weighted average share price on November 12, 2020.

Urovant Sciences advised that the acquisition bid has already been unanimously approved by each company’s board of directors and is expected to close in Q1/21 subject to approval by a majority of minority shareholders.

Get Our Free Metatrader 4 Indicators - Put Our Free MetaTrader 4 Custom Indicators on your charts when you join our Weekly Newsletter

Get our Weekly Commitment of Traders Reports: - See where the biggest traders (Hedge Funds and Commercial Hedgers) are positioned in the futures markets on a weekly basis.

Pierre Legault, lead independent member of Urovant’s Board of Directors and chairman of the special committee, remarked, “After careful consideration and consultation with our financial advisors, the special committee of the Urovant Board of Directors has found that Sumitovant’s offer represents exceptional value for shareholders.”

Urovant Sciences’ President and CEO James Robinson commented, “Our business is growing, and we remain focused on the potential opportunity to launch vibegron in 2021, pending FDA approval…Sumitovant is our largest investor, and we have been partnering closely with them on plans to efficiently launch vibegron and achieve scale as quickly as possible. We believe that this investment represents a vote of confidence in Urovant’s future success and will put us in an even stronger position to bring vibegron to market as a new treatment option for patients with overactive bladder and to continue advancing our promising development pipeline.”

The firm stated that after the transaction is fully approved and finalized, Urovant will become a wholly owned subsidiary of Sumitovant and will continue to be based in Irvine, Calif.

The company pointed out that it is still expecting U.S. Food and Drug Administration (FDA) action on its New Drug Application submission for vibegron in the U.S. by December 26, 2020.

Urovant Sciences specializes in creating commercializing innovative therapies for urologic conditions. The company’ lead product candidate is vibegron, “an oral, once-daily small molecule beta-3 agonist that is being evaluated for overactive bladder.” The firm advised that it submitted a New Drug Application to the FDA in December 2019 to seek approval of vibegron in treating OAB patients.

Sumitovant Biopharma is a global biopharmaceutical firm that is owned 100% by Sumitomo Dainippon Pharma, which is among the top-10 listed pharmaceutical companies in Japan. In addition to its Urovant holdings, Sumitovant is the majority shareholder of Myovant Sciences and wholly owns Enzyvant Therapeutics, Spirovant Sciences and Altavant Sciences.

Urovant Sciences started off the day with a market capitalization of around $262.1 million with approximately 31.66 million shares outstanding and a short interest of about 2.8%. UROV shares opened 93% higher today on the news at $15.98 (+$7.70, +93.00%) over yesterday’s $8.28 closing price and reached a new 52-week high price this morning of $16.08. The stock has traded in a very tight range today between $15.98 and $16.08 per share and is closed at $16.02 (+$7.74, +93.48%).


1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.